ArticleBlood2012
Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 66 citations in OpenAlex.
- Drug-loaded erythrocytes: Modern approaches for advanced drug delivery for clinical use.Heliyon · 2024Review
- Comparative Study of Nanoparticle Blood Circulation after Forced Clearance of Own Erythrocytes (Mononuclear Phagocyte System-Cytoblockade) or Administration of Cytotoxic Doxorubicin- or Clodronate-Loaded Liposomes.International journal of molecular sciences · 2023Article
- Drug transport by red blood cells.Frontiers in physiology · 2023Review
- Half-Life Extension and Biodistribution Modulation of Biotherapeutics via Red Blood Cell Hitch-Hiking with Novel Anti-Band 3 Single-Domain Antibodies.International journal of molecular sciences · 2022Article
- Perspective on the Application of Erythrocyte Liposome-Based Drug Delivery for Infectious Diseases.Membranes · 2022Review
- Modularity of RBC hitchhiking with polymeric nanoparticles: testing the limits of non-covalent adsorption.Journal of nanobiotechnology · 2022Article
- Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis.Journal of nanobiotechnology · 2022Review
- Red Blood Cell Hitchhiking: A Novel Approach for Vascular Delivery of Nanocarriers.Annual review of biomedical engineering · 2021Article
- Article
- Fibrin-modulating nanogels for treatment of disseminated intravascular coagulation.Blood advances · 2021Article
- Bivalent engagement of endothelial surface antigens is critical to prolonged surface targeting and protein delivery in vivo.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Enhancement of the blood-circulation time and performance of nanomedicines via the forced clearance of erythrocytes.Nature biomedical engineering · 2020Article
- Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics.Pharmaceutics · 2020Review
- Recombinant human thrombomodulin attenuated sepsis severity in a non-surgical preterm mouse model.Scientific reports · 2020Article
- The transcription factor ERG regulates a low shear stress-induced anti-thrombotic pathway in the microvasculature.Nature communications · 2019Article
- Differentiation of Baboon (Cells · 2019Article
- Red blood cells as an efficient in vitro model for evaluating the efficacy of metallic nanoparticles.3 Biotech · 2019Review
- Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery.Theranostics · 2019Review
- Red Blood Cell Membrane Processing for Biomedical Applications.Frontiers in physiology · 2019Review
- Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis.JCI insight · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
Abstract
Thrombin generates fibrin and activates platelets and endothelium, causing thrombosis and inflammation. Endothelial thrombomodulin (TM) changes thrombin's substrate specificity toward cleavage of plasma protein C into activated protein C (APC), which opposes its thrombotic and inflammatory activities. Endogenous TM activity is suppressed in pathologic conditions, and antithrombotic interventions involving soluble TM are limited by rapid blood clearance. To overcome this problem, we fused TM with a single chain fragment (scFv) of an antibody targeted to red blood cells. scFv/TM catalyzes thrombin-mediated generation of activated protein C and binds to circulating RBCs without apparent damage, thereby prolonging its circulation time and bioavailability orders of magnitude compared with soluble TM. In animal models, a single dose of scFv/TM, but not soluble TM, prevents platelet activation and vascular occlusion by clots. Thus, scFv/TM serves as a prodrug and provides thromboprophylaxis at low doses (0.15 mg/kg) via multifaceted mechanisms inhibiting platelets and coagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.